A brewing trade fight between the US and China may unravel a nearly two-year effort to ease intellectual-property rules for producing Covid-19 vaccines and cast further doubt on the
US President
“The second-largest economy in the world, which has Covid vaccines and mRNA technology, doesn’t need the waiver,” Deputy US Trade Representative
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.